Articles tagged with Antibodies
Scientists have developed a new approach to treating autoimmune diseases by creating artificial antibodies that target the MMP9 enzyme. These 'metallobodies' mimic natural inhibitors and selectively block two members of the MMP family, preventing symptoms in mice with inflammatory conditions.
Researchers found that prior immune response to one serotype can influence interaction with virus subtypes in a subsequent infection, increasing risk of severe disease. The study provides new insights into the complex interplay between viral genetics and immune system response.
Scientists at Rensselaer Polytechnic Institute have designed a new method to create antibodies that neutralize the harmful protein particles leading to Alzheimer's disease. The process targets specific portions of the toxic protein, allowing for better understanding and potential treatment of similar diseases like Parkinson's.
Neuromyelitis optica (NMO) is an inflammatory autoimmune disease that damages optic nerves and spinal cord. Mayo Clinic researchers have identified critical steps leading to myelin destruction, which could lead to better diagnosis and treatment of the disease.
Researchers aim to generate antibodies against human proteins without animal testing, using bacterial and yeast libraries to identify active genes. This could lead to a better understanding of human disease and potential therapeutic targets.
A team of Caltech biologists has developed a new, more potent HIV antibody that targets the virus's entry site. The antibody shows increased effectiveness against multiple subtypes of HIV, paving the way for potential clinical testing and improved vaccine development.
A new malaria vaccine combines multiple proteins from various parasite types, inducing antibodies against a wide range of parasites. The vaccine has shown improved protection in children in endemic areas and could be especially useful for vulnerable groups.
A new treatment for the deadly Hendra virus has proven successful in primate tests, with all 12 treated animals surviving after infection. The antibody m102.4 has shown strong activity against both Hendra and Nipah viruses.
Early humans' immune system responded strongly to Neu5Gc, a sugar molecule found on most animal cells. This response likely reduced reproductive success in males with high levels of Neu5Gc, driving the evolution of human ancestors.
Scientists at Cold Spring Harbor Laboratory have identified a new approach to treating diabetes and obesity by targeting the PTP1B enzyme, which is crucial in regulating insulin signaling. By oxidizing a specific cysteine residue, the enzyme's activity is temporarily halted, allowing for improved insulin sensitivity.
Scientists have identified a novel type of antibody that works against pneumococcal bacteria by causing them to clump together, leading to the expression of genes that could kill some of their siblings. This finding could improve vaccines against pneumonia and reduce hospitalizations and deaths from pneumococcal disease.
Scientists at A*STAR's IMCB discover that antibodies can directly target intracellular oncoproteins like PRL-3 to suppress cancer growth. This breakthrough finding offers hope for cancer prevention and has the potential to expand the scope of tailor-made antibody therapy and cancer vaccines.
Bleeding calf syndrome affects new-born calves, caused by low blood cell counts and bone marrow depletion. A vaccine against BVDV has been linked to the condition through anti-MHC class I antibodies produced by mothers.
Rush researchers identified a molecule, an antibody, in the bloodstream of infertile women that could be used to screen for high-risk individuals or those with early-stage ovarian cancer. Significant levels of mesothelin antibodies were found in women with premature ovarian failure and ovulatory dysfunction.
A newly discovered human antibody recognized multiple strains of the flu virus, providing a promising lead for developing a longer-lasting vaccine. The antibody, dubbed CH65, binds tightly to the receptor pocket on the influenza virus, making it less affected by mutations.
Researchers have discovered an antibody that can neutralize a broad range of flu strains, potentially reducing the need for annual vaccinations. The antibody, called CH65, mimics key aspects of the influenza virus's entry point and could guide the development of vaccines targeting multiple strains.
A specialized regulatory T cell that expresses three specific genes has been discovered to shut down the mass production of antibodies in the immune system. This finding has potential implications for treating cancer and autoimmune diseases.
A novel virus spread through a California monkey colony in late 2009, infecting over a third of the monkeys and causing devastating respiratory illness. The virus also infected two human researchers and family members, demonstrating its ability to jump between species.
Researchers have developed a method to predict whether someone will produce high levels of antibodies against a flu shot, allowing for the rapid development of vaccines and monitoring of suboptimal immune responses in vulnerable populations. The test uses gene activity data to identify predictive signatures with up to 90% accuracy.
The University of Colorado Boulder's BioServe Space Technologies will carry five CU-Boulder-built payloads aboard the final space shuttle mission. The payloads include an antibody experiment to treat bone loss in astronauts and a salmonella vaccine development project.
A new discovery has been made in the fight against plague and bacterial pneumonias by researchers at the Trudeau Institute. They have identified a single component of the plague causing bacterium that can be used as a vaccine, offering a potential safer alternative to existing vaccines.
A study by USC researchers reveals that the inefficiency of activation-induced deoxycytidine deaminase is key to generating antibody diversity, a crucial component of the immune system. The enzyme's random process creates mutations in immunoglobulin genes, producing a diverse array of antibodies.
A new comment published in The Lancet states that numerous studies failed to replicate the findings of a 2009 XMRV detection in CFS patients. Contamination of laboratory reagents is blamed for the association between XMRV and chronic fatigue syndrome, leaving the field without a confirmed cause.
Researchers at UC Davis discovered that Lyme disease bacteria accumulate in lymph nodes, triggering a strong immune response but one that is not effective against the infection. The study suggests that B. burgdorferi has developed a novel strategy to subvert the immune system, allowing it to both provoke and evade an effective response.
Research suggests that the swine flu outbreak of winter 2009-2010 was more widespread than previously realized, with almost half of Scottish adults carrying antibodies to the virus. The study found that people from deprived areas were twice as likely to contract the virus.
Researchers develop a new therapy to prime tumors before radiotherapy, reducing damage to healthy tissue. The treatment shows effective targeting of tumors with minimal side effects.
New research in the FASEB Journal suggests that flawed antibody production could compromise resistance to infections during long-term missions. Scientists found that antibodies produced in space are less effective than those produced on Earth, posing a serious risk for astronauts.
A new test measuring multiple parameters including PSA and six antibodies found in the blood of men with prostate cancer is more sensitive and specific than the conventional PSA test. The A+PSA assay reduces false-positives and shows great potential to improve prostate cancer diagnosis.
A new antibody called 5750 has been developed by researchers at Ruhr-University Bochum to label specific stem cells in the nervous system. The antibody targets a sugar residue on the cell surface called LewisX, which is found on different types of neural stem cells.
Three Ontario projects focused on biomonitoring, gene function, and synthetic antibody production will further knowledge and discovery in these fields. The funding will support the creation of new methods to monitor environmental change and improve treatment options for cancers.
A new blood-based test has the potential to diagnose Systemic Lupus Erythematosus (SLE) more quickly and accurately, allowing doctors to prescribe the right medication and prevent flares. The test uses a small chip to detect biomarkers in the body, creating a unique 'fingerprint' for each patient.
Feral pigs in eastern North Carolina have been found to host significant numbers of parasites that can be transmitted to humans, including Toxoplasma gondii and Trichinella. The study's findings highlight the potential health risk posed by feral pigs to both domestic swine and humans.
Researchers at UC San Diego School of Medicine have discovered a potential cancer biomarker in non-human sialic acid antibodies, which can also be used as a treatment to suppress tumor growth. The study found that patients with carcinomas have elevated levels of antibodies to one specific Neu5Gc-containing sugar chain.
A new injection has been developed to limit the devastating consequences of heart attacks and strokes, with potential applications in transplant surgery. The injection targets a key enzyme responsible for inflammation, neutralizing its effects and significantly reducing tissue damage.
A study found that extending the HPV vaccine dosing schedule to every 3 months was comparable to the standard schedule in terms of antibody concentration levels. This alternative schedule may provide a more feasible option for expanding vaccine use in developing countries.
Researchers have discovered a unique antibody from llamas that can interfere with the toxins produced by Clostridium difficile, a health problem affecting hundreds of thousands of patients worldwide. This discovery promises to provide a much-needed alternative treatment option for this increasing healthcare problem.
Researchers have developed an experimental vaccine against the human norovirus, generating a strong immune response in mice. The vaccine uses a novel viral vector-based method and showed promise in inducing high levels of antibodies and a robust white blood cell response in animals.
Researchers have made a breakthrough in developing a universal blood product that can be transfused without matching the donor and recipient's blood types. This new approach uses immunocamouflage to hide blood cells from antibodies, allowing for a reduced risk of fatal immune reactions.
Babies born to HIV-infected mothers have lower antibody levels, making them more susceptible to illnesses like pneumonia and meningitis. Vaccination shows promise in boosting their immune response.
A study found that infants exposed to HIV at birth but not infected had lower antibody levels to diseases like pertussis, tetanus, and pneumococcus. This group is vulnerable to infections and has higher mortality rates compared to uninfected infants.
A recent study published in the Journal of Biological Chemistry reveals that PSA (prostate-specific antigen) levels correlate with prostate cancer progression due to a complex formed between PSA and cell surface receptor GRP78. This binding stimulates pathways promoting tumor growth, cell movement, and blocking apoptosis.
Researchers found that people infected with 2009 H1N1 and recovered produced antibodies protective against a variety of flu strains. The study suggests incorporating these defenses into a vaccine could provide broad protection against all influenza strains.
Researchers identified broadly protective antibodies against a variety of flu strains in patients infected with the 2009 H1N1 pandemic strain, suggesting a pan-influenza vaccine may be feasible. The antibodies could guide efforts to design a vaccine providing long-lasting protection against a wide spectrum of flu viruses.
Researchers at Stanford University School of Medicine discovered that many cancer cells carry a protein called calreticulin (CRT), which signals circulating immune cells to engulf and digest them. This 'eat me' signal counteracts a separate 'don't eat me' signal, CD47, previously found in earlier studies.
A recent study from the University of North Carolina found that widely used histone antibodies may not always recognize their intended targets, but instead bind to other sites. The researchers used a new approach to generate modified histone proteins and tested commercial antibodies, which often showed off-target binding issues.
Researchers at NIAID envision a universal flu vaccine that elicits an unnatural immune response, protecting against multiple flu strains. By targeting a shared region of the flu protein HA, scientists hope to develop a broadly protective vaccine that could replace seasonal vaccines.
A UNC-led research team developed a searchable database of more than 200 commonly used antibodies to help genetic scientists precisely test DNA. The database addresses the issue of specificity in antibody tests, which can affect gene regulation and human diseases.
Research suggests moderate to severe COPD may involve an auto-immune component, with 34% of patients having abnormal ANA and AT levels in their blood. The study found a significant association between these auto-antibodies and impairment of lung function.
Early and abundant HIV antibodies are ineffective in blocking infection due to their inability to recognize the virus until it has invaded a healthy cell. The study reveals that the virus creates two versions of the 'Achilles heel' that different types of antibodies need to target, making effective defense challenging.
A new imaging method has been developed at Stanford to quickly and accurately locate and count the myriad connections between nerve cells in unprecedented detail. The method, array tomography, combines high-resolution photography with specialized fluorescent molecules to capture information and converts it into imagery.
A new Georgetown University Medical Center study found that up to 40% of scleroderma patients will not be correctly diagnosed using a commercial screening test. The researchers evaluated over 200 scleroderma patients and found that the test failed to identify patients with specific antibodies, highlighting the need for alternative test...
A phase I clinical trial at University of Texas M. D. Anderson Cancer Center found an antibody loaded with an anti-cancer agent produced complete or partial remissions in 38 percent of patients with relapsed or therapy-resistant Hodgkin lymphoma.
A Finnish study found that children born in spring are more likely to develop food allergies due to sensitization during fetal development. Research suggests a peak in birch and alder pollen levels in April-May may contribute to this association.
A study analyzing H1N1 antibody levels suggests a third wave is unlikely in 2010. Adults aged 50-79 years are at a higher risk of severe outcomes if infected.
A study published in PLOS Medicine found that pooled nucleic acid amplification testing is not cost-effective at recommended antibody testing intervals, except for clinics serving men who have sex with men. However, decreasing the antibody testing interval to 6 months or 5 years made it cost-saving in all settings.
A study published in The Lancet Infectious Diseases suggests that infant immunity to hepatitis B lasts for at least 5 years after primary vaccination, making booster shots unnecessary. The research, led by Alessandro Zanetti, found that children vaccinated with hexavac maintained protective antibody levels for over 5 years.
Researchers have developed a new method for visualizing individual virus particles, enabling a more detailed understanding of these minute pathogens. The technique, known as surface plasmon resonance microscopy, allows for the detection and measurement of viral mass, with a detection limit rivaling conventional methods by three to four...
A study of 216 patients with open-angle glaucoma found that older patients and those with abnormal anticardiolin antibodies experienced faster visual field decline. Reducing intraocular pressure modestly slowed this decline, particularly in younger patients.
Researchers identified a new signaling pathway between TACI and MyD88 that regulates the immune response. This interaction may cause both protective antibodies against infections and excessive immune reactions in autoimmune diseases.
DZNE and LMU researchers have identified alpha secretase enzyme ADAM10, which cleaves amyloid precursor protein without forming beta-amyloid plaques. This discovery opens up new possibilities for diagnosing and preventing Alzheimer's disease.